Champions Oncology Inc (CSBR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Champions Oncology Inc (CSBR) has a cash flow conversion efficiency ratio of -0.306x as of January 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.34 Million) by net assets ($4.38 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See CSBR defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Champions Oncology Inc - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Champions Oncology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Champions Oncology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Champions Oncology Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Fifth District Bancorp, Inc. Common Stock
NASDAQ:FDSB
|
0.000x |
|
Klevo Rewards Limited
AU:KLV
|
N/A |
|
Grimoldi SA
BA:GRIM
|
-0.023x |
|
Ladprao General Hospital Public Company Limited
BK:LPH
|
0.077x |
|
Kyungdong City Gas Co Ltd
KO:267290
|
0.112x |
|
Seouleaguer Co. Ltd
KQ:043710
|
0.033x |
|
seha corporation
KO:027970
|
0.076x |
|
Nasmedia Co. Ltd
KQ:089600
|
-0.051x |
Annual Cash Flow Conversion Efficiency for Champions Oncology Inc (1996–2025)
The table below shows the annual cash flow conversion efficiency of Champions Oncology Inc from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see Champions Oncology Inc stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-04-30 | $3.77 Million | $7.39 Million | 1.958x | -39.28% |
| 2024-04-30 | $-1.90 Million | $-6.14 Million | 3.225x | +278.02% |
| 2023-04-30 | $4.64 Million | $3.96 Million | 0.853x | +19.44% |
| 2022-04-30 | $9.10 Million | $6.50 Million | 0.714x | +415.62% |
| 2021-04-30 | $7.43 Million | $-1.68 Million | -0.226x | -139.72% |
| 2020-04-30 | $5.10 Million | $2.90 Million | 0.570x | -31.52% |
| 2019-04-30 | $2.24 Million | $1.86 Million | 0.832x | -98.30% |
| 2018-04-30 | $-25.00K | $-1.23 Million | 49.040x | +790.70% |
| 2017-04-30 | $400.00K | $-2.84 Million | -7.100x | +73.81% |
| 2016-04-30 | $238.00K | $-6.45 Million | -27.109x | -2168.67% |
| 2015-04-30 | $8.06 Million | $-9.63 Million | -1.195x | -11.28% |
| 2014-04-30 | $3.20 Million | $-3.43 Million | -1.074x | -91.58% |
| 2013-04-30 | $7.60 Million | $-4.26 Million | -0.560x | -156.60% |
| 2012-04-30 | $-5.28 Million | $-5.23 Million | 0.990x | +134.85% |
| 2011-04-30 | $19.00K | $-54.00K | -2.842x | -113.43% |
| 2010-04-30 | $1.58 Million | $-2.10 Million | -1.332x | -187.32% |
| 2009-04-30 | $1.92 Million | $-888.00K | -0.463x | -312.75% |
| 2008-04-30 | $3.64 Million | $792.40K | 0.218x | -27.53% |
| 2007-04-30 | $-261.06K | $-78.47K | 0.301x | +114.48% |
| 2006-04-30 | $-670.51K | $-93.97K | 0.140x | +44.39% |
| 2005-04-30 | $-366.80K | $-35.60K | 0.097x | -87.51% |
| 2004-04-30 | $-92.70K | $-72.05K | 0.777x | -34.29% |
| 2003-04-30 | $-209.75K | $-248.12K | 1.183x | -81.89% |
| 2002-04-30 | $-5.00K | $-32.68K | 6.530x | +581.82% |
| 2001-04-30 | $151.06K | $144.68K | 0.958x | +4754.15% |
| 2000-04-30 | $891.69K | $-18.35K | -0.021x | -116.65% |
| 1999-04-30 | $890.00K | $110.00K | 0.124x | -72.34% |
| 1998-04-30 | $940.00K | $420.00K | 0.447x | +164.02% |
| 1997-04-30 | $650.00K | $110.00K | 0.169x | +342.56% |
| 1996-04-30 | $430.00K | $-30.00K | -0.070x | -- |
About Champions Oncology Inc
Champions Oncology, Inc., a technology-enabled research company, provides technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft technology platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers translational oncology solutions that utilizes its technology platform … Read more